Cannabis Bioscience International Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
Cannabis Bioscience International Holdings reports a net loss of $103,933 for the third quarter ended February 28, 2026, amid ongoing liquidity and going concern challenges.
OID
Cannabis Bioscience International Holdings reports significantly increased net losses and a critical cash position, raising substantial doubt about its ability to continue as a going concern.
OID
Cannabis Bioscience International Holdings, Inc. reported a significant revenue decline and increased net loss, raising substantial doubt about its ability to continue as a going concern.
OID
10-Q/A: Cannabis Bioscience International Holdings Amends Q3 Report to Correct Errors and Update Share Count
Cannabis Bioscience International Holdings files an amendment to its Q3 report to correct financial statement errors, update the share count, and include XBRL data.
OID
Cannabis Bioscience International Holdings reports increased revenue for the nine months ended February 28, 2025, but continues to struggle with net losses and a going concern uncertainty.
OID
Cannabis Bioscience International Holdings files an amended 10-Q for the quarter ended November 30, 2024, showing improved revenue and reduced losses compared to the previous year.
OID
Cannabis Bioscience International Holdings reports increased revenue for the six months ended November 30, 2024, but continues to face challenges related to its going concern status.
OID
10-Q/A: Cannabis Bioscience International Holdings Files Amended Quarterly Report After Immaterial Errors
Cannabis Bioscience International Holdings has filed an amended 10-Q report to correct minor errors in its financial discussion, while the core financials remain unchanged.
OID
Cannabis Bioscience International Holdings, Inc. saw a significant increase in revenue during the first quarter of 2025, primarily driven by growth in clinical trial contracts, but continues to face challenges as a going concern.
OID
Cannabis Bioscience International Holdings reports a net loss of $515,410 for the nine months ended February 29, 2024, alongside a decrease in revenue compared to the previous year.
OID
Cannabis Bioscience International Holdings reports a net loss of $306,217 for the six months ended November 30, 2023, amidst ongoing operational adjustments and the impact of the COVID-19 pandemic.